Medipost Appoints Former Samsung Biologics Executive Vice President Min Hoseong as President

Overseeing Global Business and CDMO Operations

Transition to Co-CEO System with Oh Wonil

Pursuing Overseas Commercialization of Cartistem in North America, Europe, and China

Medipost announced on September 2 that it had appointed Min Hoseong, former Executive Vice President of Samsung Biologics, as its new President.

Min Hoseong, President of Medipost

Medipost plans to officially appoint President Min as CEO through an upcoming extraordinary general meeting of shareholders and board of directors’ resolution. By transitioning to a co-CEO system with existing CEO Oh Wonil and President-designate Min, the company seeks to enhance expertise in both domestic and global operations and accelerate its efforts to expand into international markets. This is the company’s strategic direction.

President Min holds a Bachelor's degree in Molecular Biology from UC Berkeley and a Doctorate in Molecular Biology from UCLA. He began his career as a researcher at global pharmaceutical company Amgen, served as a Senior Researcher at the Samsung Advanced Institute of Technology, Executive Director and Head of DS at Samsung Bioepis, CEO of the global biotechnology firm GenScript ProBio, and Head (Executive Vice President) of the CDMO Development Center at Samsung Biologics. According to Medipost, President Min is considered a global business expert with over 20 years of experience in areas such as research and development (R&D), business development (BD), and contract development and manufacturing (CDMO) for biopharmaceuticals including gene and cell therapies.

Medipost’s strategy with the introduction of the co-CEO system is to maximize specialization by business sector and the speed of decision-making. CEO Oh will be responsible for domestic business areas, including Cartistem, the GMP Center, cord blood business, health functional food segment, and the SCT business division. President Min will oversee the global business division, US and Japanese subsidiaries, and CDMO affiliate OmniaBio. He will also be in charge of business development and global clinical and commercialization strategies in North America, Europe, China, and other overseas markets.

In particular, the company is stepping up efforts to bring its stem cell therapy for degenerative osteoarthritis, Cartistem, to overseas markets. Cartistem has currently met all primary and secondary endpoints in Phase 3 clinical trials in Japan, and a Biologics License Application (BLA) is being prepared for submission in Japan. In the US, Medipost obtained single clinical trial approval that allows for approximately 20–30% reduction in development costs and a three to six-month acceleration in the development timeline compared to the traditional approach, and patient dosing has already begun. Building on this, Medipost plans to solidify strategies for launching and commercializing in North American and Japanese markets, while expanding its business scope to Europe, China, and other regions.

A Medipost representative said, "By recruiting President Min, who has demonstrated extensive experience and achievements in global pharmaceutical and CDMO sectors, this will serve as a key momentum for Medipost’s leap to become a global biotech company. Through the co-CEO system, we will establish a swift and efficient management environment and maximize the global value of major pipelines such as Cartistem."

President Min commented, "It is meaningful to join Medipost as co-CEO, a company with proven technological capabilities and outstanding clinical achievements. I will ensure local milestones, such as the BLA submission in Japan and clinical trials in the US, proceed without delay and will further accelerate commercialization in global markets, not only in North America and Japan, but also in Europe, China, and beyond, thereby enhancing corporate and shareholder value."

This content was produced with the assistance of AI translation services.